TISSUE-BASED BIOSENSOR MARKET

INTRODUCTION

Tissue-based biosensors can typically be created from genetically altered cells or through direct genetic alteration that introduces biosensor proteins into an animal tissue. The concentration of the molecule being detected is converted by biosensor cells into a physical signal that can be precisely quantified.

Hormones, medications, and poisons can all be detected and measured using biosensors that are based on the tissue architecture of living animals. Tissue-based biosensors have the potential to be used in a variety of biomedical sciences, including physiology, pharmacology, and biodefense.

Tissue-based biosensors can typically be created from genetically altered cells or through direct genetic alteration that introduces biosensor proteins into an animal tissue. The concentration of the molecule being detected is converted by biosensor cells into a physical signal that can be precisely quantified. 

TISSUE-BASED BIOSENSOR MARKET  SIZE AND FORECAST

The Global tissue-based biosensor market  accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

NEW PRODUCT LAUNCH

The most adaptable foundation for tissue-based biosensors is provided by biophotonics. Fluorescence or bioluminescence are the two types of light that biosensor cells can produce, and of the two, bioluminescence has the advantage of not needing a light source for input and having a better signal-to-noise ratio in live organisms than fluorescence.

By using fusion proteins that can produce resonance energy transfer, protein-protein interactions can be used to detect almost any chemical.

The Tissue-Based Biosensors Project was started by the Defense Advance Research Projects Agency (DARPA), which offers funding to research and private institutions to create two- and three-dimensional tissue-based biosensors that will accurately and effectively detect the presence of biological and chemical weapons.

The project aims to develop cell-based systems that can recognise threats to human health on the battlefield, enhance and prolong the life of cells used as biosensors, and prevent cellular biosensors from degrading while in use. It also aims to improve the performance of cells for the detection of chemical and biological weapons.

The primary technology used by UBI to assess various blood indicators. The company's well-known subsidiaries include Universal Biosensors Pty Ltd and Hemostasis Reference Laboratory Inc. It is ranked among the top biosensor businesses worldwide.

COMPANY PROFILE

• Abbott Laboratories
• DowDuPont Inc.
• Bio-Rad International
• Masimo Corporation
• Molecular Devices Corp.

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many tissue-based biosensors are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global tissue-based biosensor and key vendor selection criteria
3. Where is the tissue-based biosensor manufactured? What is the average margin per unit?
4. Market share of Global tissue-based biosensor market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global tissue-based biosensor in-house
6. key predictions for next 5 years in Global tissue-based biosensor market
7. Average B-2-B tissue-based biosensor market price in all segments
8. Latest trends in tissue-based biosensor market, by every market segment
9. The market size (both volume and value) of the tissue-based biosensor market in 2023-2030 and every year in between?
10. Production breakup of tissue-based biosensor market, by suppliers and their OEM relationship